BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31668133)

  • 21. High Prevalence of Gene Fusions and Copy Number Alterations in Pediatric Radiation Therapy-Induced Papillary and Follicular Thyroid Carcinomas.
    Hess JR; Newbern DK; Beebe KL; Walsh AM; Schafernak KT
    Thyroid; 2022 Apr; 32(4):411-420. PubMed ID: 34915766
    [No Abstract]   [Full Text] [Related]  

  • 22. Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing.
    Chang CC; Chang YS; Huang HY; Yeh KT; Liu TC; Chang JG
    Hum Pathol; 2018 Aug; 78():151-158. PubMed ID: 29753010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
    Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
    Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
    Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.
    Fang Y; Ma X; Zeng J; Jin Y; Hu Y; Wang J; Liu R; Cao C
    Cell Physiol Biochem; 2018; 50(1):169-178. PubMed ID: 30278442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do Molecular Profiles of Primary
    Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
    Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma.
    Rubinstein JC; Brown TC; Christison-Lagay ER; Zhang Y; Kunstman JW; Juhlin CC; Nelson-Williams C; Goh G; Quinn CE; Callender GG; Udelsman R; Lifton RP; Korah R; Carling T
    BMC Cancer; 2016 Aug; 16():646. PubMed ID: 27538953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
    Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
    Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
    Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
    Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
    Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
    Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.
    Lu Z; Sheng J; Zhang Y; Deng J; Li Y; Lu A; Zhang J; Yu H; Zhang M; Xiong Z; Yan H; Diplas BH; Lu Y; Liu B
    J Pathol; 2016 May; 239(1):72-83. PubMed ID: 27071483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.
    Minna E; Devecchi A; Pistore F; Paolini B; Mauro G; Penso DA; Pagliardini S; Busico A; Pruneri G; De Cecco L; Borrello MG; Sensi M; Greco A
    Front Endocrinol (Lausanne); 2023; 14():1267499. PubMed ID: 37867524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
    Colombo C; Muzza M; Proverbio MC; Tosi D; Soranna D; Pesenti C; Rossi S; Cirello V; De Leo S; Fusco N; Miozzo M; Bulfamante G; Vicentini L; Ferrero S; Zambon A; Tabano S; Fugazzola L
    Thyroid; 2019 Feb; 29(2):237-251. PubMed ID: 30501571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
    Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
    Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.